- Home
- RDI vs INAB Comparison
RDI vs INAB Comparison
Compare RDI & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDI | INAB |
|---|---|---|
| Founded | 1937 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 22.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RDI | INAB |
|---|---|---|
| Price | $1.05 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $180.00 |
| AVG Volume (30 Days) | 27.6K | ★ 37.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.94 | $0.12 |
| 52 Week High | $1.65 | $4.20 |
Technical Indicators
Market Signals| Indicator | RDI | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 42.84 |
| Support Level | $1.00 | $1.52 |
| Resistance Level | $1.16 | $2.55 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 55.81 | 38.98 |
Price Performance
Historical ComparisonAbout RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.